The AMA has collected more than 400 educational and other resources to provide evidence-based recommendations for physicians and policymakers.

FDA naloxone guidance: before and after

An infographic showing how the September 22, 2022 US Food and Drug Administration (FDA) Guidance operates to remove barriers to access for harm reduction programs.             Special thanks to: Alliance For The People, Remedy, and Nabarun Dasgupta. Infographic On 2022 Fda Naloxone Distribution Guidance. 2022.

Total dispensed prescriptions for naloxone in retail pharmacies (2012-2021)

From 2016 to 2021, naloxone prescriptions dispensed from pharmacies increased from almost 134,000 to nearly 1.2 million prescriptions.

AMA Opioid Task Force naloxone recommendations

Updated August 2017

Surgeon General’s Advisory on Naloxone and Opioid Overdose

Surgeon General of the United States Public Health Service, VADM Jerome Adams, MD

Naloxone for Opioid Safety

Management of Opioid Withdrawal and Overdose II

Discussing Naloxone for Opioid Safety

Naloxone product comparison chart for brand and generic injectable and intranasal formulations

Prescribe to Prevent

Overdose prevention tools and best practices

Harm Reduction Coalition

Public Policy Statement on the Use of Naloxone for the Prevention of Drug Overdose Deaths

When Seconds Count: “Opioid Overdose Resuscitation” card

Putting Naloxone Into Action!

AMA Substance Use and Pain Care Task Force

The AMA Substance Use and Pain Care Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s drug overdose epidemic—and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.

Learn More

Be part of the solution.

Join the AMA today and help us lead the effort
to reverse the nation’s opioid epidemic.